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Abstract
Background: Proliferative vitreoretinopathy (PVR) is a leading cause of blindness after failed
retinal reattachment surgery. PVR is characterized by the proliferation, migration and contraction
of retinal pigmented epithelial cells (RPE), and these cellular responses are influenced by the
expression and function of integrin receptors. The effect of a cyclic integrin antagonist containing
the amino acid sequence Arg-Gly-Asp-D-Phe-Val (RGDfV), specific for the integrin receptors α vβ 3
and α vβ 5, was investigated on basic fibroblast growth factor (bFGF), platelet derived growth factor-
BB (PDGF-BB), and serum induced human RPE proliferation, migration, invasion and attachment to
the extracellular matrix. Furthermore, the effects of bFGF and PDGF-BB regulated expression of
integrins α vβ 3 and α vβ 5 on RPE cells was examined.
Methods: The effect of a cyclic integrin antagonist and a control peptide (0.01 µg/ml to 300 µg/
ml) was investigated on serum or cytokine (bFGF or PDGF-BB pretreatment) induced human fetal
RPE cell proliferation by H3-thymidine uptake. The effect of the cyclic integrin antagonist on RPE
cell attachment onto different extracellular matrices (laminin, collagen IV, fibronectin), RPE cell
invasion stimulated by PDGF-BB or serum, and migration stimulated by PDGF-BB, vascular
endothelial growth factor (VEGF) or serum was explored. PDGF-BB and bFGF modulation of the
integrin receptors α vβ 3 and α vβ 5 was evaluated by flow cytometry.
Results: The integrin antagonist did not inhibit DNA synthesis stimulated by serum, bFGF, or
PDGF-BB treatment. RPE attachment onto fibronectin was inhibited in a concentration range of 1–
10 µg/ml (p < 0.05). Attachment of the RPE cells onto collagen IV and laminin was inhibited in a
range of 3–10 µg/ml (p < 0.05). Serum and PDGF-BB stimulated migration was inhibited by the
cyclic integrin antagonist in a concentration range of 1–10 µg/ml (p < 0.05). Furthermore, the cyclic
integrin antagonist inhibited PDGF-BB stimulated RPE cell invasion through fibronectin (3µg/ml:
66% inhibition, p < 0.001). In each of these experiments, the control peptides had no significant
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effects. PDGF-BB and bFGF pretreatment of RPE cells increased the expression of integrin
receptors α vβ 3 (bFGF: 1.9 fold, PDGF-BB: 2.3 fold) and α vβ 5 (bFGF: 2.9 fold, PDGF-BB: 1.5 fold).
Conclusion: A selective inhibition of the integrin receptors α vβ 3 and α vβ 5 through a cyclic integrin
antagonist is able to inhibit RPE cell attachment, migration and invasion. Since these steps are of
importance for the progression of PVR, a cyclic integrin antagonist should be further evaluated for
the treatment of this disease.
Background
Integrins are a family of heterodimeric, non-covalently
bound cell surface receptors, which mediate cell-cell and
cell to extracellular matrix (ECM) adhesion. They are
transmembrane glycoproteins consisting of a larger α  and
a smaller β  subunit. In mammals, 18 α - and 8 β  integrin
genes encode polypeptides that combine to form 24 αβ
heterodimeric receptors [1]. By mediating cell-cell and
cell-matrix contact, the integrins are involved in a spec-
trum of physiologic and pathologic processes. Integrin
expression is modulated by several cytokines, growth fac-
tors and the extracellular matrix in different cell types [2].
The integrins α vβ 3 and α vβ 5 have been shown to be of par-
ticular significance for the progression of neovasculariza-
tion. Both integrin receptors contain RGD sequences
containing the amino acid sequence Arg-Gly-Asp. Vit-
ronectin receptor integrins of the α v – chain subfamily
interact with their target proteins via the tripeptide
sequence RGD (NH2-arginine-glycine-aspartic acid-
COOH) [3,4]. The blockage of these RGD receptor
sequences induces endothelial cell apoptosis by inhibit-
ing their binding to the ECM [5,6]. In addition fibroblast
attachment onto fibrinogen, a substep involved in wound
healing, is inhibited by blockage of the α vβ 3  integrin
receptor [7]. Therefore, the integrin α vβ 3 plays a critical
role during wound repair as an adhesion receptor and as
a signaling receptor [8]. As an adhesion receptor, it has the
exceptional ability to bind vitronectin, fibronectin and
fibrinogen, the three major proteins present in the wound
provisional matrix [9].
In proliferative vitreoretinopathy (PVR), a disease of the
posterior eye characteristically induced by trauma or
failed retinal reattachment surgery, integrins are also of
importance for the progression of the disease [10,11].
PVR, an exaggerated wound healing process, is character-
ized by the proliferation, migration and contraction of ret-
inal pigment epithelial cells (RPE), fibroblasts, glial cells
and macrophages. PVR membranes are formed on, or
under the sensory retina; their contraction may lead to ret-
inal detachment and blindness. RPE cells play a dominant
role in the pathobiology of the disease [12]. Growth fac-
tors including basic fibroblast growth factor (bFGF),
platelet derived growth factor-BB (PDGF-BB), and vascu-
lar endothelial growth factor (VEGF), and the ECM mole-
cule fibronectin, regulate proliferation, migration and
invasion of the RPE cell and are expressed in PVR mem-
branes [12,13]. Fibronectin is an adhesive substrate for
both the integrin receptors α vβ 3 and  α vβ 5 [14]. Several
studies have identified integrins α vβ 3, α vβ 5, integrin alpha
subunits 2,3,4,5,6, V, and integrin beta subunits 1, 2, 3 on
RPE cells and cells within PVR membranes [15-17]. The
ECM-cell interactions are thought to be mediated largely
through this family of cell surface receptors. Because cell-
ECM interaction is important in the process of wound
healing, one could predict that integrins would be actively
involved in the pathogenesis of PVR. For PVR, it was
shown in vivo, that tractional retinal detachment could be
inhibited [11] by blockage of integrin-ECM binding by an
RGD containing disintegrin.
Peptide antagonists specific for individual integrins have
been developed, including cyclic RGD peptides selective
for the α v integrin [18], the α vβ 3 integrin [19], and the α vβ 5
integrin [18-21]. Sequence alterations in the backbone of
the RGD-containing cyclic peptides that result in confor-
mational differences in the interatomic distance between
the Cβ  atoms of Arg and Asp, have been shown to correlate
with selective peptide recognition [18,22,23].
In this study we investigated the modulatory effect of the
cytokines PDGF-BB and bFGF on the expression of the
RGD containing integrin receptors α vβ 3  and  α vβ 5  on
human fetal RPE cells. Furthermore, the effect of a specific
cyclic integrin antagonist that blocks the integrin recep-
tors α vβ 3 and α vβ 5, was investigated for its effects on RPE
attachment, proliferation, migration and invasion. A spe-
cific cyclic integrin antagonist was chosen for its higher
affinity and stronger binding capacity to the α vβ 3 and α vβ 5
integrins compared to a non-cyclic integrin antagonist
[24,18].
Methods
All cell culture solutions, media and ECM molecules
(fibronectin, laminin and vitronectin) were purchased
from Sigma (Sigma, St. Louis, MO).
Isolation and culture of human RPE cells
Human RPE cells were isolated from fetal donor eyes (ges-
tation time over 22 weeks) which were obtained from the
Anatomic Gift foundation (Woodbine, GA) as has beenBMC Ophthalmology 2005, 5:16 http://www.biomedcentral.com/1471-2415/5/16
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described [25]. RPE cells were seeded onto laminin-coated
6 well plates (Fisher Scientific, Tustin, CA) using DMEM
with 10 % fetal bovine serum, 1 % penicillin/streptomy-
cin and glutamine. Cells from passage 3 to 5 were used in
all experiments.
Synthesis of the cyclic integrin antagonist and its control 
peptide
The cyclic integrin antagonist RGDfV, specific for the inhi-
bition of integrins α vβ 3 and α vβ 5 [18-21] and the control
peptide RADfV were synthesized as described [6] at the
USC/ Norris Cancer Peptide synthesis facility. The pep-
tides were dissolved in Hank's Balanced Salt Solution
(HBSS), and stored at -80°C. HPLC analysis revealed a
purity > 99% of the synthesized peptide.
Flow cytometry
RPE cells (30,000 cells/well) were treated for 5 days with
the cytokines bFGF and PDGF-BB at a concentration of 10
ng/ml in 6 well plates. Cells were detached, fixed with 4 %
paraformaldehyde, blocked with 5 % goat serum for 30
minutes, centrifuged at 4°C, and incubated with a mono-
clonal mouse antibody against α vβ 3 or  α vβ 5 (5  µg/ml)
(Chemicon, CA) for one hour. After washing, a fluores-
cein conjugated secondary antibody (Chemicon, CA)
directed against the mouse antibodies was added in a
dilution of 1:100 for one hour. The expression of the
integrin receptors α vβ 3 or α vβ 5 was measured using a fluo-
rescent-activated cell sorter (FACStar plus, Becton Dickin-
son, Mountain View, CA). Forward and side light scatter
was used to gate the desired scattered events (RPE cells)
from dead cells and debris. The fluorescent index was
determined by multiplying the percentage of cells by their
mean fluorescence. At least 10,000 cells were evaluated/
experiment and all experiments were performed in
triplicate.
Cell counting and viability studies
Subconfluent, bFGF (10 ng/ml) or PDGF-BB (10 ng/ml)
pre-stimulated RPE cells were seeded at a density of 8 ×
104 cells per well in 6 well plates containing DMEM with
10 % FBS and the cyclic integrin antagonist or the control
peptide (0.01 µg/ml, 0.1 µg/ml, 1 µg/ml, 30 µg/ml and
300 µg/ml). The cells were exposed during the prolifera-
tion assay to 10% FBS or the cytokines bFGF and PDGF-
BB (10 ng/ml). After 3 days of culture, the cell number was
determined using a hemocytometer. The experiments
were performed six times, each in triplicate. Cell viability
was estimated by observation of cell morphology and by
exclusion of 0.4 % trypan blue solution [26].
3H-thymidine uptake
RPE cells (10,000 cells/well) were seeded into DMEM
with 10 % FBS in 24 well plates with the cyclic integrin
antagonist or the control peptide (0.01 µg/ml, 0.1 µg/ml,
1 µg/ml, 30 µg/ml and 300 µg/ml). To determine a possi-
ble stronger effect of the cyclic integrin antagonist on RPE
cell proliferation, cells were pre-stimulated for 5 days with
bFGF (10 ng/ml) or PDGF-BB (10 ng/ml) (R&D Systems,
Minneapolis, MN) to induce an upregulation of the
integrin receptors α vβ 3 or α v β  5. After the pre-incubation,
cells were seeded in DMEM with 10 % FBS, with the cyclic
integrin antagonist or control peptide, and bFGF (10 ng/
ml) or PDGF-BB (10 ng/ml). Cells were treated for three
days with the peptides, then 3H-thymidine uptake was
measured as described previously [25]. Results are pre-
sented as the percentage of control values.
Migration assay
Migration was performed in a modified Boyden chamber
(Falcon, Becton Dickinson Labware, Franklin Lakes, NJ).
Subconfluent RPE cells, which have been pre-exposed to
the cyclic integrin antagonist peptide (0.001 ng/ml, 0.01
ng/ml, 0.1 ng/ml, 1 ng/ml, 3 ng/ml and 10 ng/ml) or the
control peptide (10 µg/ml) over night were seeded into
DMEM with 1 % FBS into the upper part of a Boyden
chamber (50,000 cells/chamber). The cyclic integrin
antagonist was added directly to the upper part of the
chamber (0.001 ng/ml, 0.01 ng/ml, 0.1 ng/ml, 1 ng/ml, 3
ng/ml, or 10 ng/ml). To evaluate nonspecific activity of
the integrin antagonist, a control peptide (10 µg/ml) was
used. The lower part of the chamber was filled with
DMEM with 1 % FBS containing the chemoattractant
PDGF-BB (10 ng/ml) or the ECM molecule fibronectin
(30 ng/ml). RPE cells were incubated for 8 hours in a
humidified CO2-incubator. Then the cells in the upper
part were scraped away and the membrane was fixed with
1/2 strength Karnovsky's solution and stained with 0.25
% Richardson's solution. RPE cells on the lower side of
the membrane were counted with the help of an inverted
microscope and a grid (Carl Zeiss, Jena, Germany) in five
random high power fields (200 X) in triplicate.
Cell attachment
Ninety-six well plates were coated with the ECM mole-
cules laminin, fibronectin or collagen IV (25 µg/ml). RPE
cells were pre-incubated with the cyclic integrin antago-
nist (concentrations as above) or control peptide (10 µg/
ml) over night. Then 15 × 103 cells, suspended in 100 µl
DMEM with the cyclic or control peptide were seeded in
each well and allowed to attach for 60 minutes. A tetrazo-
lium MTT [3-(4,5-dimethylthiazolyl-2)-2,5-diphe-
nyltetrazolium bromide] solution (20 µl/well)
(Boehringer Mannheim, Indianapolis, IN, USA) was
added for 5 hours of incubation. Then the supernatants
were decanted, 150 µl of 100% DMSO added, and the
cells were placed on a shaker for 10 minutes. Absorbance
of the cells was measured at 550 nm with a Dynatech MR
600 spectrophotometric microplate reader.BMC Ophthalmology 2005, 5:16 http://www.biomedcentral.com/1471-2415/5/16
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Invasion assay
RPE cell invasion was examined in a modified Boyden
chambers. The insert membrane was coated overnight
with fibronectin (25 µg/ml). Subconfluent RPE cells were
pretreated overnight with the cyclic integrin antagonist (3
µg/ml) or the control peptide (3 µg/ml). An RPE cell sus-
pension (50,000 cells/0.1 ml) in DMEM with 0.4 % FBS
and 3 µg/ml cyclic integrin antagonist or control peptide
was added into the upper part of the chamber. 600 µl
DMEM with 0.4% FBS and PDGF-BB (10 µg/ml) was
added into the lower part of the chamber. Invasion was
measured with and without PDGF-BB stimulation after 5
hours at 37°C (95 % air/ 5 % Co2). After PBS washing and
methanol fixation (10 minutes at 4°C), counterstaining
with hematoxylin was performed. Cells in the upper
chamber were wiped away. RPE cells that invaded the
lower surface of the membrane were quantified by cell
counting (320 × magnification).
Statistical analysis
All experiments were repeated in triplicate. Standard devi-
ations and averages were calculated. The data obtained
were analyzed for significance using one way analysis of
variance (ANOVA). Data with a p-value of less then 0.05
were considered to be statistically significant.
Results
The cyclic integrin antagonist does not inhibit RPE cell 
proliferation
The RPE cells were stimulated to incorporate thymidine
by either 10% serum or by 10 ng/ml bFGF or 10 ng/ml
PDGF-BB (p < 0.01). Neither the integrin antagonist, nor
control peptide showed any significant effect on serum,
PDGF-BB or bFGF stimulated DNA synthesis. (data not
shown). In addition, cell counting showed no effects of
the integrin antagonist or the control peptide on serum or
cytokine stimulated proliferation. Furthermore, a lack of
toxicity for the integrin antagonist and the control peptide
in the concentration range tested (0.01 µg/ml, 0.1 µg/ml,
1 µg/ml, 30 µg/ml and 300 µg/ml) was determined by use
of the trypan blue exclusion assay (data not shown).
bFGF and PDGF-BB upregulate surface expression of α vβ 3 
and α vβ 5
Pre-stimulation of RPE cells for 5 days with the cytokines
PDGF-BB and bFGF (10 ng/ml) increased the expression
of the integrin receptors α vβ 3 and α vβ 5 (Fig. 1; representa-
tive flow cytometric study). Incubation with 10 ng/ml
bFGF upregulated the expression of α vβ 3 (1.9 fold) and
strongly enhanced the expression of α vβ 5  (2.9 fold).
PDGF-BB (10 ng/ml) strongly enhanced α vβ 3 (2.3 fold),
and less strongly upregulated surface expression of α vβ 5
(1.5 fold).
The cyclic integrin antagonist inhibits RPE attachment 
onto ECM
RPE cell attachment onto fibronectin was inhibited signif-
icantly in the range of 1 to 10 µg/ml of cyclic integrin
antagonist (p < 0.05) (Fig. 2A). A concentration of 10 µg/
ml control peptide showed no effect. RPE cell attachment
was inhibited 18 % with 1 µg/ml (p = 0.03), 23 % with 3
µg/ml (p < 0.005) and 27 % with 10 µg/ml (p < 0.001)
onto fibronectin. An ID50 of 18.5 µg/ml cyclic integrin
antagonist was calculated for the RPE cell attachment
onto fibronectin. The attachment onto collagen IV was
inhibited 25 % with 3 µg/ml (p < 0.001), and 29 % with
10 µg/ml (p < 0.001). Lower concentrations showed no
significant effect. An ID50 of 17.2 µg/ml cyclic peptide was
calculated for RPE cell attachment onto collagen IV.
Attachment onto laminin was inhibited by the cyclic
integrin antagonist in the range of 3–10 µg/ml (3 µg/ml,
27 % inhibition (p < 0.001); 10µg/ml: 23 % inhibition (p
< 0.001). An ID50 of 21.7 µg/ml was calculated for the
inhibition of RPE cell attachment onto laminin.
The cyclic integrin antagonist inhibits RPE cell migration
The ECM component fibronectin (30 ng/ml) induced
chemotaxis when placed as a soluble agent in the lower
part of the Boyden chamber (Fig. 2B). This migratory
response was inhibited by the cyclic integrin antagonist
but not by the control peptide. RPE cell migration was
inhibited in a concentration range of 1–10 µg/ml (1µg/
ml, 18 % inhibition (p < 0.001); 3 µg/ml, 23 % inhibition
(p < 0.001); 10 mg/ml, 27 % inhibition (p < 0.001)). An
ID50 of 18.5 µg/ml integrin antagonist was calculated for
the serum induced migration. The migratory response
induced by PDGF-BB (10 ng/ml) (93 % stimulation of
migration) was diminished by the cyclic integrin antago-
nist. (1µg/ml, 26 % inhibition (p < 0.001); 3 µg/ml, 66 %
inhibition (p < 0.001); and 10µg/ml, 74 % inhibition (p
< 0.001)). An ID50 of 5.8 µg/ml was calculated for the
inhibition of PDGF-BB induced migration of RPE cells.
VEGF induced a migratory response of RPE cells by 39 %.
This migratory response was inhibited by the cyclic
integrin antagonist in a concentration range of 3–10 µg/
ml (p < 0.01).
The cyclic integrin antagonist inhibits PDGF-BB stimulated 
invasion through fibronectin
PDGF-BB strongly stimulated RPE cell invasion (77 %, (p
< 0.001)) through fibronectin coated onto the lower sur-
face of a membrane insert in a modified Boyden chamber.
This invasion was inhibited by the cyclic integrin antago-
nist (3 µg/ml, 66 % inhibition (p < 0.001)). The control
peptide had no significant effect on invasion (Fig. 2C). An
ID50 of 2.3 µg/ml was calculated for the effects of the cyclic
integrin antagonist on PDGF-BB induced RPE invasion
through fibronectin.BMC Ophthalmology 2005, 5:16 http://www.biomedcentral.com/1471-2415/5/16
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>A. Expression of the integrin receptors α vβ 3 and α vβ 5 after pretreatment with the cytokine bFGF in a concentration of 10 ng/ ml for 5 days Figure 1
A. Expression of the integrin receptors α vβ 3 and α vβ 5 after pretreatment with the cytokine bFGF in a concentration of 10 ng/
ml for 5 days. B. Expression of the integrin receptors α vβ 3 and α vβ 5 after pretreatment with the cytokine PDGF-BB in a con-
centration of 10 ng/ml for 5 days.BMC Ophthalmology 2005, 5:16 http://www.biomedcentral.com/1471-2415/5/16
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A. RPE attachment on fibronectin, laminin and collagen IV Figure 2
A. RPE attachment on fibronectin, laminin and collagen IV. The cells were pretreated before the assay with the cyclic integrin 
antagonist, or the control peptide (10 µg/ml). Untreated RPE cells were used in addition as a standard (ST). B. RPE cell migra-
tion induced by PDGF-BB, VEGF and fibronectin. The effect of the cyclic integrin antagonist or the control peptide (cp) on 
migration is shown. (ST = untreated RPE cells) C. Effect of the cyclic integrin antagonist, (3 ug/ml) or the control peptide on 
RPE invasion through fibronectin. Cell invasion through fibronectin (F) was stimulated with PDGF-BB (10 ng/ml). Nonspecific 
effects were excluded by the use of a cyclic control peptide. DMEM without PDGF-BB was used as a control in the assay.
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Discussion
These data provide support for the suggestion that inhibi-
tion of the integrin receptors α vβ 3 and α vβ 5 by a specific
cyclic integrin antagonist is feasible for inhibiting RPE cell
attachment, migration and invasion and may serve as an
adjunctive therapy for disorders such as PVR. Integrins
have been shown to influence cell signaling pathways that
promote cell proliferation in concert with cytokines [27].
Interestingly, our data show that cyclic integrin inhibition
of α vβ 3 and α vβ 5 had no effect on serum, PDGF-BB or
bFGF induced proliferation of RPE. Since we also show
that bFGF and PDGF-BB upregulate both α vβ 3 and α vβ 5,
and that proliferation is not inhibited in these stimulated
cells, we can infer that the lack of effect of the cyclic pep-
tide on proliferation is not due to lack of integrin expres-
sion. Consistent with the lack of effect on proliferation,
we found that the cyclic integrin inhibitor did not induce
significant cell death. This suggests that in the conditions
studied here, the effect of integrin inhibition by the cyclic
peptide on survival and proliferation of RPE cells may dif-
fer from previously described effects on endothelial cells
[28], specific tumor cells [29] and mammary epithelial
cells [30].
Cell attachment of RPE cells onto fibronectin, laminin
and collagen IV was inhibited by the cyclic integrin antag-
onist. Because substrate attachment and interaction is
important for activated RPE function [31], it is reasonable
to predict that anti-adhesive therapy holds promise for the
therapy of PVR. The cyclic integrin antagonist has been
shown previously to inhibit specific ligand binding or cell
adhesion events mediated by α vβ 3 or α vβ 5 [18]. Blockage
of RPE attachment onto laminin, collagen IV and
fibronectin is of specific interest, because of the strong
expression of these matrix proteins in PVR [12]. The ECM
fibronectin reacts with the α vβ 3 receptor with high specif-
icity and affinity, supporting cell adhesion to this matrix
protein. The α vβ 5  receptor binds in a similar way to
fibronectin [32]. The blockage of α vβ 3 and α vβ 5 thus pro-
vides a reasonable explanation for the decreased attach-
ment of RPE onto collagen IV, fibronectin and laminin in
the presence of the inhibitory cyclic peptide.
RPE cell migration is another important process in the
development of PVR. Without migration, RPE cells would
not gain access to the vitreous and form vitreoretinal
membranes. For RPE cells, it was shown previously that
monoclonal antibody inhibition of integrin subunit β  1
inhibits RPE cell migration from wound edges in organ
culture [14]. Integrin signaling results in actin cytoskele-
ton polymerization, which in turn regulates cell shape
and motility [33]. The α vβ 3  receptor appears to be
involved in pathways that regulate intracellular pH and
intracellular Ca2+ [34] and may therefore be involved in
migration in response to motility factors and extracellular
matrix components [35]. The same range of concentration
of the cyclic peptide inhibited migration induced by both
soluble fibronectin and PDGF-BB. This result may in part
be due to the finding that PDGF-BB induced migration is
mediated by signaling pathways that are also used by
integrin receptors [36-38].
The cyclic integrin antagonist had a particularly strong
effect on RPE invasion into fibronectin. This may be due
to the concurrent effects of the peptide on the inhibition
of adhesion, migration and proteolytic activity since each
of these steps may play a critical role in the invasion of the
ECM.
The cyclic integrin antagonist described here blocks both
α vβ 3 and α vβ 5. In contrast, highly selective integrin antag-
onists such as LM609 block only α vβ 3. Therefore, a
stronger inhibitory effect of the cyclic integrin antagonist
can be expected as has been shown in tumors [36]. While
increased specificity could result in lower toxicity, we did
not find that the cyclic integrin antagonist inhibited thy-
midine incorporation, or that it increased trypan blue
uptake in the concentrations tested.
Conclusion
The cyclic integrin antagonist RGDfV inhibits RPE migra-
tion, attachment and invasion, and should be further
investigated as a potential adjuvant pharmacological
treatment for PVR.
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